This site is intended for healthcare professionals
Drug information


Read time: 17 mins
Last updated: 06 May 2020
Published: 24 Jul 2020

4.1 Therapeutic indications

Rheumatological disorders and connective tissue diseases such as:

• rheumatoid arthritis (for primary chronic disease and maintenance therapy)

• systemic lupus erythematosus (non-organ threatening disease)

• mild-moderate juvenile dermatomyositis

Severe or debilitating allergic conditions, not treatable in a conventional manner such as:

• bronchial asthma in children

• bronchial asthma in adults (for maintenance therapy)

Sarcoidosis in children and for maintenance therapy in adults

Acquired haemolytic anaemia (autoimmune, for maintenance therapy)

Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.




The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC ( Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).